Phase 3 Readout~month

Phase 3 Topline: An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immuno

July 1, 2027

Company: AMICUS THERAPEUTICS, INC. (FOLD)
Drug: infantile-onset
Indication: Glycogen Storage Disease Type II Infantile Onset

Other upcoming events for FOLD

Phase 3 ReadoutPhase 3 Topline: An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects With F

Phase 3 ReadoutPhase 3 Topline: An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Trea

Patent ExpiryPatent/Exclusivity Expiry: STEGLATRO

Patent ExpiryPatent/Exclusivity Expiry: SEGLUROMET

Patent ExpiryPatent/Exclusivity Expiry: STEGLUJAN

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immuno — FOLD Phase 3 Readout | BioSniper